Articles

The deal—potentially totaling upwards of $100 million—strengthens the company’s selection of US generic prescription products.




 Dr. Reddy’s Acquires Mayne Pharma Portfolio

Stats point to a 14.9% decline compared to January of last year.




Initiative intends to facilitate regulatory compliance within the pharma distribution space. 




With the help of traceability, new feature prioritizes efficiency and safety, from production to patient.

Hoping to accelerate the drug delivery process, production is expected to begin as early as 2025. 




Following numerous successful trial runs, vaccine production is expected to reach 700 million.




Expansion expected to increase global capacity by 75%. 



Enhancements to help keep products frozen for over 144 hours, company says. 




Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies. 



New 25,000 square-foot facility will help grow customers’ gene therapy programs.


